Nanexa
Nanexa invites to a webcast to present the positive clinical data from NEX-22 once monthly GLP-1, liraglutide project published on last Friday
Referring to the clinical results presented last Friday Nanexa invites to a webcast hosted by Infront Direkt studios at 14:00 pm today, Monday November 25th.
Chairman Dr. Göran Ando, CEO David Westberg and Director Business Development Otto Skolling will present the results as well as an overview of the GLP-1 segment and plans going forward.
“These clinical results put us in a completely new, very exciting situation with a potential to transform the type-2 diabetes and obesity treatment regime to less frequent treatments say David Westberg, CEO Nanexa.”
The comment will be available here.
Viewers will have the opportunity to ask questions via chat.
The comment will also be published on Nanexa's website afterwards.
Datum | 2024-11-25, kl 08:00 |
Källa | MFN |